Vitruvias Recalls Superpotent Thyroid Tablets Nationwide
Vitruvias Therapeutics is voluntarily recalling 1,955 bottles of Thyroid Tablets due to superpotency. The FDA classifies this as a Class I recall.
What this means for you
Highest-severity recall. Risk of serious injury or death is documented or strongly suspected. Stop using the product now and follow the agency's instructions.
Our severity reasoning: The FDA has classified this recall as Class I, which is the highest severity level for drug recalls indicating a reasonable probability that use of the product will cause serious adverse health consequences or death.
Plain-English summary
Vitruvias Therapeutics is voluntarily recalling 1,955 bottles of Thyroid Tablets, USP, 1/2 Grain (30 mg). The affected product is identified by Lot # 504950 and has an expiration date of 09/30/2026. The recall was initiated on August 21, 2026, and the product was distributed nationwide in the United States.
The FDA has classified this recall as Class I, the most serious classification, because the product is a superpotent drug. Superpotency means the tablets contain more active ingredients than labeled, which can lead to serious adverse health consequences if taken by patients. The recall was initiated by the firm and is currently ongoing.
Patients who have been prescribed this specific lot of Thyroid Tablets should stop using the product and contact their healthcare provider for further instructions. The recall was reported to the FDA on September 23, 2026.
The recalled product
- Product
- THYROID (THYROID)
- Brand
- THYROID
- Manufacturer
- VITRUVIAS THERAPEUTICS INC
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 1,955
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 504950
- Exp Date: 09/30/2026.
Distribution
Distributed nationwide across the United States.
Related recalls
Same hazard · superpotency
See all →- HighAripiprazole 10 mg tablets recalled after testing superpotent in one lot
FDA (Drugs) · 2025-09-24
- ModerateHYDROmorphone Hydrochloride 50 mg Cassettes Recalled for Superpotency
FDA (Drugs) · 2025-04-30
- HighLevothyroxine Sodium Tablets Recalled Nationwide for Potency Variance
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled for Subpotent and Superpotent Content
FDA (Drugs) · 2024-12-18
- ModerateTriamcinolone Acetonide Cream USP Recalled for Out-of-Specification Potency Variance
FDA (Drugs) · 2024-11-27